American Heart Journal
Volume 148, Issue 3 , Pages 393-398 , September 2004

The Triiodothyronine for Infants and Children Undergoing Cardiopulmonary Bypass (TRICC) study: Design and rationale

  • Michael A. Portman, MD

      Affiliations

    • Division of Cardiology, Department of Pediatrics, Seattle, Wash, USA
    • Corresponding Author InformationReprint requests: Michael A. Portman, MD, Children's Hospital and Regional Medical Center 4G-1, 4800 Sand Point Way NE, Seattle WA 98105, USA.
    • ,
  • Collette Fearneyhough, RN

      Affiliations

    • Division of Cardiology, Department of Pediatrics, Seattle, Wash, USA
    • ,
  • Tom R. Karl, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, Children's Hospital and the University of California San Francisco School of Medicine, San Francisco, Calif, USA
    • ,
  • Elizabeth Tong, RN

      Affiliations

    • Division of Cardiology, Department of Pediatrics, San Francisco, Calif, USA
    • ,
  • Kristy Seidel

      Affiliations

    • Division of Cardiology, Department of Pediatrics, Seattle, Wash, USA
    • ,
  • Antonio Mott, MD

      Affiliations

    • Division of Cardiology, Department of Pediatrics, Texas Children's Hospital and the Baylor College of Medicine, Houston, Tex, USA
    • ,
  • Gordon Cohen, MD, PhD

      Affiliations

    • Division of Cardiovascular Surgery, Department of Surgery, Children's Hospital and Regional Medical Center and the University of Washington School of Medicine, Seattle, Wash, USA
    • ,
  • Theresa Tacy, MD

      Affiliations

    • Division of Cardiology, Department of Pediatrics, San Francisco, Calif, USA
    • ,
  • Mark Lewin, MD

      Affiliations

    • Division of Cardiology, Department of Pediatrics, Seattle, Wash, USA
    • ,
  • Lester Permut, MD

      Affiliations

    • Division of Cardiovascular Surgery, Department of Surgery, Children's Hospital and Regional Medical Center and the University of Washington School of Medicine, Seattle, Wash, USA
    • ,
  • Mary Schlater, RN

      Affiliations

    • Division of Cardiology, Department of Pediatrics, Seattle, Wash, USA
    • ,
  • Anthony Azakie, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, Children's Hospital and the University of California San Francisco School of Medicine, San Francisco, Calif, USA

Received 25 November 2003 ,Accepted 29 March 2004.

References 

  1. Bennett-Guerrero E, Jimenez JL, White WD, et al.  Cardiovascular effects of intravenous triiodothyronine in patients undergoing coronary artery bypass graft surgery (a randomized, double-blind, placebo- controlled trial. Duke T3 Study group). [see comments] JAMA. 1996;275:687–692
  2. Klemperer JD, Klein I, Gomez M, et al.  Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med. 1995;333:1522–1527
  3. Bettendorf M, Schmidt KG, Tiefenbacher U, et al.  Transient secondary hypothyroidism in children after cardiac surgery. Pediatr Res. 1997;41:375–379
  4. Portman MA, Fearneyhough C, Ning X, et al.  Triiodothyronine repletion in infants during cardiopulmonary bypass for congenital heart surgery. J Thorac Cardiovasc Surg. 2000;120:604–608
  5. Dyke CM, Ding M, Abd-Elfattah AS, et al.  Effects of triiodothyronine supplementation after myocardial ischemia. Ann Thorac Surg. 1993;56:215–222
  6. Mullis-Jansson SL, Argenziano M, Corwin S, et al.  A randomized double-blind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery. J Thorac Cardiovasc Surg. 1999;117:1128–1134
  7. Mainwaring RD, Capparelli E, Schell K, et al.  Pharmacokinetic evaluation of triiodothyronine supplementation in children after modified Fontan procedure. Circulation. 2000;101:1423–1429
  8. Bettendorf M, Schmidt KG, Grulich-Henn J, et al.  Tri-iodothyronine treatment in children after cardiac surgery (a double-blind, randomised, placebo-controlled study). Lancet. 2000;356:529–534
  9. Chowdhury D, Ojamaa K, Parnell VA, et al.  A prospective randomized clinical study of thyroid hormone treatment after operations for complex congenital heart disease. J Thorac Cardiovasc Surg. 2001;122:1023–1025
  10. Mainwaring RD, Lamberti JJ, Nelson JC, et al.  Effects of triiodothyronine supplementation following modified Fontan procedure. Cardiol Young. 1997;7:194–200
  11. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39:499–503
  12. Hoffman TM, Wernovsky G, Atz AM, et al.  Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation. 2003;107:996–1002
  13. Gay RG, Raya TE, Lancaster LD, et al.  Effects of thyroid state on venous compliance and left ventricular performance in rats. Am J Physiol Heart Circ Physiol. 1988;254:H81–88
  14. Gay R, Gustafson TA, Goldman S, et al.  Effects of l-thyroxine in rats with chronic heart failure after myocardial infarction. Am J Physiol Heart Circ Physiol. 1987;253:H341–346
  15. Novitzky D, Human PA, Cooper DKC. Inotropic effect of triiodothyronine (t3) following myocardial ischemia and cardiopulmonary bypass (an experimental study in pigs). Ann Thorac Surg. 1988;45:50–55
  16. DiPierro FV, Bavaria JE, Lankford EB, et al.  Triiodothyronine optimizes sheep ventriculoarterial coupling for work efficiency. Ann Thorac Surg. 1996;62:662–669
  17. Ferrari R, Ceconi C, Curello S, et al.  Metabolic changes during post-ischaemic reperfusion. J Mol Cell Cardiol. 1988;20:119–133
  18. Klemperer JD, Zelano J, Helm RE, et al.  Triiodothyronine improves left ventricular function without oxygen wasting effects after global hypothermic ischemia. J Thorac Cardiovasc Surg. 1995;109:457–465
  19. Mainwaring RD, Lamberti JJ, Carter TL, et al.  Reduction in triiodothyronine levels following modified Fontan procedure. J Card Surg. 1994;9:322–331
  20. Brogan TV, Bratton SL, Lynn AM. Thyroid function in infants following cardiac surgery (comparative effects of iodinated and noniodinated topical antiseptics). Crit Care Med. 1997;25:1583–1587

☆ Supported primarily by grant FD-R-1971-01 from the US Food and Drug Administration to Michael A. Portman, and NIH grants M01RR00037 and M01RR001271. Triostat provided by King Pharmaceuticals.

PII: S0002-8703(04)00155-3

doi: 10.1016/j.ahj.2004.03.029

American Heart Journal
Volume 148, Issue 3 , Pages 393-398 , September 2004

Article Tools